Days after a CRL and damning reports of trial misconduct, a troubled biotech beats a hasty retreat from Europe
Two weeks after little Sesen Bio popped its inflated stock price $SESN with news of an FDA rejection — and a week after the remaining …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
